The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USAPCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.
Translation of favourable effects of evolocumab on coronary plaque to CV outcomes 00:34
Evidence of incremental benefit of anti-atherosclerotic therapy beyond statin treatment 01:26
Study of cognitive function in a subset of FOURIER patients 02:31
SPIRE reinforces the importance of targeting dyslipidemia 03:39
Treating patients with PCSK9 inhibitors can achieve effective risk reductions above and beyond statins 05:39
Educational information
This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice
The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME
Faculty & Disclosures
Prof. Stephen J. Nicholls - South Australian Health & Medical Research Institute, Adelaide, Australia
Funding
Funding was provided by an unrestricted educational grant from Amgen
